ReviewCold Spring Harbor perspectives in medicine2012
Clinical immunologic interventions for the treatment of type 1 diabetes.
Review in Cold Spring Harbor perspectives in medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Therapeutic Effects of BCG Vaccination on Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Journal of diabetes research · 2020Pooled it
- Preexisting insulin autoantibodies predict efficacy of otelixizumab in preserving residual β-cell function in recent-onset type 1 diabetes.Diabetes care · 2015Trial
- Fludarabine disrupts the STAT1/AhR interaction to attenuate type 1 diabetes by inducing tolerogenic dendritic cells along with targeting effector T cells.Molecular medicine (Cambridge, Mass.) · 2026Article
- Insights on the role of anti-inflammatory and immunosuppressive agents in the amelioration of diabetes.Diabetology international · 2023Review
- Exposure to persistent organic pollutants alters the serum metabolome in non-obese diabetic mice.Metabolomics : Official journal of the Metabolomic Society · 2022Article
- Dysregulation of β-Cell Proliferation in Diabetes: Possibilities of Combination Therapy in the Development of a Comprehensive Treatment.Biomedicines · 2022Review
- Formation of pancreatic β-cells from precursor cells contributes to the reversal of established type 1 diabetes.Cellular immunology · 2021Article
- A Question of Tolerance-Antigen-Specific Immunotherapy for Type 1 Diabetes.Current diabetes reports · 2020Review
- Immunotherapy via PD-L1-presenting biomaterials leads to long-term islet graft survival.Science advances · 2020Article
- Article
- LPS enhances CTB-INSULIN induction of IDO1 and IL-10 synthesis in human dendritic cells.Cellular immunology · 2019Article
- Current Status on Immunological Therapies for Type 1 Diabetes Mellitus.Current diabetes reports · 2019Review
- The impact of rare and low-frequency genetic variants in common disease.Genome biology · 2017Review
- Diabetes: Immunotherapy for T1DM--still not there yet.Nature reviews. Endocrinology · 2013Article
- Bringing genome-wide association findings into clinical use.Nature reviews. Genetics · 2013Review
- Primary and secondary prevention of Type 1 diabetes.Diabetic medicine : a journal of the British Diabetic Association · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 1 diabetes is an autoimmune disease, hence the rationale for immunotherapy to halt disease progression. Based on knowledge gained from other autoimmune diseases and from transplantation, the first immunointervention trials used immunosuppressive drugs, e.g., cyclosporin, in patients with recently diagnosed type 1 diabetes. Although remarkable, the effect vanished following drug withdrawal. Efforts were then devoted to devise strategies to induce/restore self-tolerance and avoid chronic immunosuppression. Various approaches were identified from work in spontaneous models of autoimmune diabetes, including the use of β-cell autoantigens and monoclonal antibodies directed at relevant immune molecules such as costimulatory ligands, T-cell receptor molecules such as CD3, and B cells. Phase II and phase III trials were launched, results of which are now available. Although the endeavor is challenging, the experience gained indicates that immunotherapy appears as the real hope of inducing long-term remission of the disease provided the treatment is started early and that protocols are adapted based on lessons from the past.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.